Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study

Jonathan Zipursky[1], Erin M. Macdonald[2], Simon Hollands[2], Tara Gomes[2,3,4,5], Muhammad M. Mamdani[2,3,4,6,7], J. Michael Paterson[2,4,8], Nina Lathia[5], David N. Juurlink[1,2,4,9¶]*

1 Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, 2 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada, 3 Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada, 4 Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada, 5 Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada, 6 Applied Health Research Centre, St. Michael's Hospital, Toronto, Ontario, Canada, 7 King Saud University, Riyadh, Saudi Arabia, 8 Department of Family Medicine, McMaster University, Hamilton, Ontario, Canada, Canada, 9 Sunnybrook Research Institute, Toronto, Ontario, Canada

Introduction

Proton-pump inhibitors (PPIs) are among the most widely prescribed drugs in the world, with more than 147 million prescriptions dispensed in the United States in 2010 alone [1]. They are the mainstay of drug therapy for acid-related disorders, and have largely supplanted histamine H2 receptor antagonists owing to their superior efficacy [2–4].

Although widely regarded as safe, PPIs have been associated with a variety of adverse effects including *Clostridium difficile*-associated diarrhea [5–7], interstitial nephritis [8,9], pneumonia [10], vitamin B12 deficiency [11], and osteoporosis and fractures [12]. More recently, long-term use of PPIs has been suggested as a potential cause of hypomagnesemia [13]. Magnesium is the second most abundant intracellular cation and its homeostasis is intricately regulated by intestinal absorption and renal excretion, although the estimated prevalence of hypomagnesemia in the general population ranges from 2.5% to 15% [14,15]. The postulated mechanism of PPI-related hypomagnesemia involves inhibition of intestinal magnesium absorption via transient receptor potential melastin (TRPM) 6 and 7 cation channels [16]. Severe hypomagnesemia can be associated with malignant cardiac arrhythmias, tetany, generalized seizures, and other metabolic disturbances such as hypokalemia and hypocalcemia [17].

First described in 2006 [18], the evidence for PPI-induced hypomagnesemia has been mainly limited to case reports and small case series, with more than 30 cases published to date [18–30]. In 2011, the US Food and Drug Administration (FDA) issued a drug safety warning regarding the potential association of PPIs with hypomagnesemia, but observational studies have yielded conflicting findings [31–34]. The largest study to date evaluated patients in a single intensive care unit, and found that PPI use was associated with hypomagnesemia only among patients also receiving diuretics [31]. It is uncertain whether PPIs are a risk factor for hypomagnesemia in routine clinical practice.

Given the widespread use of PPIs, particularly in combination with other drugs that can promote hypomagnesemia, such an association may be difficult to appreciate clinically. We examined the association between outpatient PPI use and hospitalization with hypomagnesemia.

Methods

Ethics Statement

This study was approved by the Research Ethics Board of Sunnybrook Health Sciences Centre. The Institute for Clinical Evaluative Sciences (ICES) is named as a prescribed entity under section 45 of the *Personal Health Information Protection Act* (Ontario Regulation 329/04, Section 18). Under this designation, ICES can receive and use anonymous health information without consent.

Setting

We conducted a population-based case-control study of all Ontario residents aged 66 years or older between April 1st, 2002 and March 31st, 2012. These individuals had universal access to physician services, hospital care, and prescription drug coverage.

Data Sources

We identified prescription records using the Ontario Drug Benefit Database, which contains comprehensive records of prescription drugs dispensed to Ontario residents aged 65 years or older. To avoid incomplete medication records, we excluded patients during their first year of eligibility for prescription drug coverage (age 65). We obtained hospitalization data from the Canadian Institute for Health Information Discharge Abstract Database, which contains detailed clinical information, including diagnoses, for all hospital admissions in Ontario. Emergency department records were obtained from the National Ambulatory Care Reporting System. We used the Ontario Health Insurance Plan database to identify claims for physician services, the Ontario Diabetes Database [35] to ascertain the presence of diabetes, and the Ontario Congestive Heart Failure Database [36] to identify individuals with congestive heart failure. We obtained basic demographic data and date of death from the Registered Persons Database, a registry of all Ontario residents eligible for health insurance. These databases were linked in an anonymous fashion using encrypted health card numbers, and are routinely used to study drug safety [37–39].

Study Patients

We defined case patients as those hospitalized with hypomagnesemia, defined using the International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes E83.42 (hypomagnesemia) or E61.2 (magnesium deficiency). Only the first such hospitalization was considered for patients with multiple episodes. The date of hospital admission served as the index date for all analyses. For each individual enrolled as a case, we randomly selected four control patients not hospitalized with hypomagnesemia. Control patients were randomly assigned an index date within one calendar year of the corresponding case patient, and patients who were controls could later serve as cases. Four control patients were matched to each case patient according to age (within 3 years), sex, chronic kidney disease (CKD), or acute kidney injury (AKI) in the year preceding the index date, and receipt of thiazide, loop, or other diuretics in the 90 days preceding the index date, with each diuretic class considered separately. Each individual could only serve once as a control and unmatched cases were excluded. We also excluded patients with a diagnosis of hyperparathyroidism or inflammatory bowel disease in the year prior to index date because these disorders can influence magnesium balance, and we excluded individuals hospitalized for any reason in the month preceding the index date to avoid the potential confounding effects of recent hospitalization.

Assessment of PPI Exposure

We identified all outpatient prescriptions for omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole. We classified PPI exposure according to the prescription closest to the index date as either current (within 90 days preceding the index date), recent (91 to 180 days prior to the index date), or remote (181 to 365 days prior to the index date). We used this approach because many patients take PPIs intermittently, particularly for symptoms of dyspepsia or gastroesophageal reflux. Moreover, any association should manifest in patients with ongoing PPI therapy, and would therefore be most likely in current users and least likely in remote users [13]. As well, in many published reports, magnesium levels have normalized shortly after discontinuation of the PPI [13].

To test the robustness and specificity of our findings, we also examined prescriptions for histamine H2 receptor antagonists, drugs with no plausible causal link to hypomagnesemia.

Statistical Analysis

We used conditional logistic regression to estimate the odds ratio and 95% confidence intervals for the association between

hypomagnesemia and receipt of a PPI prescription. In all analyses, the reference group consisted of patients with no PPI prescription in the 365 days preceding the index date. A similar analysis was conducted for histamine H2 receptor antagonists. A subgroup analysis was performed to examine the risk of hypomagnesemia associated with PPI use amongst patients concomitantly prescribed diuretics.

We adjusted all models for confounders with standardized differences>0.10 including the number of drugs dispensed in the year preceding the index date (a validated measure of comorbidity) [40], systemic steroid use in the preceding year, any history of diabetes or heart failure in the 3 years prior to the index date, and the presence of systemic malignancy in the preceding year. We used SAS version 9.3 for all analyses (SAS Institute), and a two-tailed type 1 error rate of 0.05 as the threshold for statistical significance.

Results

During the ten-year study period, we identified 429 patients aged 66 years or older hospitalized with hypomagnesemia. We excluded 63 patients enrolled as cases (14.7%) who had been hospitalized in the prior month or had a diagnosis of inflammatory bowel disease in the previous year. The remaining 366 case patients were matched to 1,464 patients designated as controls. The characteristics of case and control patients are shown in Table 1. The median age was 78 (interquartile range [IQR] 71–83) years, and slightly more than half were women. As expected, compared with control patients, case patients received more medications and were more likely to have various comorbid conditions (Table 1).

In the primary analysis, we found that patients hospitalized with hypomagnesemia were more likely than control patients to be current users of PPIs (adjusted odds ratio, 1.43; 95% CI 1.06–1.93). Neither recent nor remote PPI use was associated with a significantly increased risk of hypomagnesemia (Table 2). The median number of tablets dispensed to patients who were cases in the 5 years preceding the index date was 1,358 (IQR 540–1,829) versus 1,176 (IQR 540–1,831) among patients who were controls. As expected, we found no association between hospitalization with hypomagnesemia and current use of histamine H2 receptor antagonists (unadjusted odds ratio 2.12, 95% CI 1.17–3.86; adjusted odds ratio 1.06; 95% CI 0.54–2.06) (Table 3). In a subgroup analysis of diuretic users, there was a higher risk of hospitalization with hypomagnesemia in patients using PPIs who

Table 1. Characteristics of patients enrolled as cases and controls.

Characteristic	Case Patients (n = 366)	Control Patients (n = 1,464)	Standardized Difference
Median (IQR) age (years)	78 (71–83)	78 (71–83)	0
Age group (years)			
66–75	149 (40.7)	596 (40.7)	0
76–85	159 (43.4)	636 (43.4)	0
86+	58 (15.5)	232 (15.8)	0
Male	145 (39.6)	580 (39.6)	0
Income quintile			
1 (lowest)	73 (19.9)	296 (20.2)	0.01
2	67 (18.3)	308 (21.0)	0.07
3	81 (22.1)	282 (19.3)	0.07
4	73 (19.9)	264 (18.0)	0.05
5	70 (19.1)	264 (18.0)	0.03
Missing	≤5[a]	50 (3.4)	0.17
Residence in LTC	32 (8.7)	103 (7.0)	0.07
Median (IQR) number of distinct drugs used in previous year[b]	12 (7–16)	7 (3–11)	0.69
Diabetes	26 (7.1)	65 (4.4)	0.12
Congestive heart failure	45 (12.3)	84 (5.7)	0.26
Liver disease	6 (1.6)	11 (0.8)	0.09
Systemic malignancy	49 (13.4)	47 (3.2)	0.46
Alcoholism	10 (2.7)	≤5[a]	0.32
Hypertension	22 (6.0)	82 (5.6)	0.02
Steroid use	54 (14.8)	116 (7.9)	0.24
CKD in one year prior	32 (8.7)	128 (8.7)	0
Loop diuretics[c]	71 (19.4)	284 (19.4)	0
Thiazide diuretics[c]	72 (19.7)	288 (19.7)	0
Other diuretics[c]	17 (4.6)	68 (4.6)	0

[a]Cell sizes lower than 6 are suppressed in accordance with institutional privacy regulations.
[b]Number of distinct drugs is a surrogate marker for comorbidity.
[c]Prescription in the prior 90 days.
CKD, chronic kidney disease; LTC, long term care.
doi:10.1371/journal.pmed.1001736.t001

Table 2. Proton pump inhibitor use and hospitalization with hypomagnesemia.

Characteristic	Number (%) of Patients with Exposure		Odds Ratio (95% Confidence Interval)	
	Case Patients (*n* = 366)	Control Patients (*n* = 1,464)	Unadjusted	Adjusted[a]
≤90 days (current)[b]	143 (39.1)	305 (20.8)	2.70 (2.08–3.51)	1.43 (1.06–1.93)
91–180 days (recent)[b]	12 (3.3)	42 (2.9)	1.59 (0.82–3.07)	1.03 (0.51–2.06)
181–365 (remote)[b]	9 (2.5)	35 (2.4)	1.37 (0.65–2.89)	0.94 (0.42–2.11)
Number of distinct drugs used in previous year	—	—	1.13 (1.11–1.16)	1.12 (1.09–1.14)
Diabetes	26 (7.1)	65 (4.4)	1.66 (1.03–2.67)	1.45 (0.85–2.47)
Congestive heart failure	45 (12.3)	84 (5.7)	2.64 (1.73–4.03)	1.70 (1.06–2.73)
Malignancy	49 (13.4)	47 (3.2)	4.71 (3.07–7.22)	3.52 (2.20–5.65)
Steroid use	54 (14.8)	116 (7.9)	2.01 (1.42–2.85)	0.97 (0.65–1.46)

[a]Adjusted for diabetes, congestive heart failure, malignancy, steroid use, and number of distinct drugs used in the past year (excluding PPI).
[b]Includes omeprazole, pantoprazole, lansoprazole, esomeprazole, and lansoprazole.
doi:10.1371/journal.pmed.1001736.t002

were also concomitantly prescribed diuretics (adjusted odds ratio, 1.73; 95% CI 1.11–2.70) (Table 4).

We anticipated that hospitalization with hypomagnesemia would be uncommon among patients treated with a PPI. Among 1,042,765 patients who commenced treatment with a PPI during the study period, 15 were hospitalized with hypomagnesemia in the subsequent 90 days, representing 3.19 such admissions (95% CI 1.95–5.2) per 100,000 new PPI prescriptions. Among all eligible control patients (*n* = 1,040,875), fewer than six individuals were admitted with hypomagnesemia within 90 days, yielding a number needed to harm at 90 days of 76,591.

Discussion

We found that current PPI therapy was associated with a 43% increased relative risk of hospitalization with hypomagnesemia in a large population of older outpatients. In contrast, no such risk was evident with more remote use of PPIs or of histamine H2 receptor antagonists. Although mild hypomagnesemia may go unnoticed, severe cases can have significant neurologic and cardiac consequences. Our findings highlight an underappreciated albeit small risk of these commonly prescribed medications.

In an analysis stratified by diuretic use, concomitant users of PPIs and diuretics had an increased risk of hospitalization with hypomagnesemia, whereas those not taking diuretics did not have an increased risk. This finding accords with that of Danziger and colleagues, who studied the association between PPIs and hypomagnesemia in an intensive care unit setting [31]. While PPI-induced hypomagnesemia is rare and most PPI users are

presumably unaffected, patients taking diuretics may be at particular risk.

Previous studies examining the association between PPIs and hypomagnesemia have found conflicting results. These studies [32–34] did not completely adjust for comorbidity and polypharmacy, important confounding factors contributing to hypomagnesemia, and two studies were limited to hospital inpatients [31,32]. Another recent case-control study by Koulouridis and colleagues found no association between outpatient PPI use and hypomagnesemia at hospital admission [33]. Some reasons why this study's conclusion may have differed from ours include the potential for misclassification of PPI use, because physician and nursing medication administration records were the primary methods of ascertaining exposure, with specificity documented to be as low as 46.2%. In contrast, we examined population-based prescriptions records and accounted for timing of the prescription. Their definition (serum magnesium concentration <1.4 mEq/l) almost certainly included less severe cases of hypomagnesemia than in our study, which examined hospitalization with hypomagnesemia—a less sensitive but more clinically meaningful outcome. Finally, their study was limited to patients at a single center hospitalized for disorders of the upper gastrointestinal tract. The largest study to date evaluated hypomagnesemia in a single intensive care unit and found that PPIs were only associated with hypomagnesemia (serum magnesium concentration <1.6 mg/dl) in patients with concurrent use of diuretics [31]. While this study supports the notion that PPIs may be a risk factor for hypomagnesemia, the generalizability of these findings to patients in routine clinical practice is uncertain.

Table 3. Histamine (H2) receptor blocker use and hospitalization with hypomagnesemia.

Timing of Most Recent H2 Blocker Prescription[a]	Number (%) of Patients with Exposure		Odds Ratio (95% Confidence Interval)	
	Case Patients (*n* = 202)	Control Patients (*n* = 808)	Unadjusted	Adjusted[b]
≤90 days (current)	19 (9.4)	41 (5.1)	2.12 (1.17–3.86)	1.06 (0.54–2.06)
91–180 days (recent)	7 (3.5)	7 (0.9)	4.14 (1.45–11.83)	3.23 (0.98–10.62)
181–365 (remote)	6 (3.0)	13 (1.6)	2.11 (0.77–5.81)	1.27 (0.44–3.71)

[a]Includes cimetidine, ranitidine, nizatidine, and famotidine.
[b]Adjusted for diabetes, congestive heart failure, malignancy, steroid use, and number of distinct drugs used in the past year (excluding PPI).
doi:10.1371/journal.pmed.1001736.t003

Table 4. Proton pump inhibitor use and hospitalization with hypomagnesemia stratified by diuretic use.

Subgroup	Number (%) of Patients with Exposure		Odds Ratio (95% Confidence Interval)	
	Case Patients ($n = 345$)	Control Patients ($n = 1,305$)	Unadjusted	Adjusted[a]
No diuretic				
No PPI	139 (65.6)	672 (84.3)	1.0 (ref)	1.0 (ref)
Current PPI use	73 (34.4)	125 (15.7)	2.96 (2.08–4.22)	1.25 (0.81–1.91)
Number of distinct drugs used in previous year	—	—	1.15 (1.12–1.19)	1.13 (1.10–1.17)
Diabetes	14 (6.6)	26 (3.3)	2.10 (1.06–4.15)	1.59 (0.71–3.56)
Congestive heart failure	17 (8.0)	12 (1.5)	6.45 (2.85–14.61)	2.41 (0.94–6.20)
Malignancy	30 (14.2)	24 (3.0)	5.44 (3.01–9.84)	3.69 (1.88–7.24)
Steroid use	30 (14.2)	41 (5.1)	3.11 (1.86–5.22)	1.21 (0.66–2.22)
Diuretic				
No PPI	63 (47.4)	350 (68.9)	1.0 (ref)	1.0 (ref)
Current PPI use	70 (52.6)	158 (31.1)	2.52 (1.68–3.77)	1.73 (1.11–2.70)
Number of distinct drugs used in previous year	—	—	1.11 (1.07–1.15)	1.09 (1.05–1.14)
Diabetes	12 (9.0)	32 (6.3)	1.51 (0.75–3.04)	1.53 (0.72–3.29)
Congestive heart failure	24 (18.0)	61 (12.0)	1.69 (0.98–2.93)	1.34 (0.74–2.44)
Malignancy	17 (12.8)	17 (3.4)	3.92 (1.98–7.79)	3.48 (1.66–7.27)
Steroid use	20 (15.0)	63 (12.4)	1.24 (0.72–2.12)	0.74 (0.40–1.36)

[a]Adjusted for diabetes, congestive heart failure, malignancy, steroid use, and number of distinct drugs used in the past year (excluding PPI).
doi:10.1371/journal.pmed.1001736.t004

The mechanism of hypomagnesemia in the setting of PPI use is poorly understood but may reflect impaired gastrointestinal absorption of magnesium. TRPM 6 and 7 cation channels in the intestine are responsible for active transport of magnesium [16]. In contrast, most other drugs associated with hypomagnesemia cause renal magnesium wasting. In patients with suspected PPI-induced hypomagnesemia, renal magnesium handling is preserved [20,23,41], although as found in our study and by others [31], this may be influenced by diuretic therapy.

We speculate that hypomagnesemia is an underappreciated consequence of PPI use, particularly given the high background use of PPIs in the general population. Whether some PPI recipients are genetically predisposed to this adverse effect is currently unknown. It has been postulated that individuals carrying heterozygous mutations of TRPM6/7 may be at especially high risk, as evidenced from observations that people with homozygous mutations of TRPM6 manifest severe hypomagnesemia [42–44]. The modest effect found in this study may in fact reflect a much larger problem with systemic magnesium balance, since only about 1% of total body magnesium is reflected in the blood [45].

The findings of this study are strengthened by the population-based nature of the data and our ability to account for virtually all PPI use, because the drugs are not sold over-the-counter in Canada. However, some limitations of our study merit emphasis. We had no access to serum magnesium levels, and the validity of hospital coding for hypomagnesemia using administrative databases is unknown. Second, our results derived from patients aged 66 years and older, and the generalizability to younger patients is unknown. Third, we cannot account for intermittent PPI use, although this would be expected to attenuate the association with hypomagnesemia. Finally, clinically significant cases of hypomagnesemia may have been missed in our analysis, particularly those presenting with arrhythmias or other metabolic abnormalities such as hypokalemia.

On the basis of the large number needed to harm (approximately 76,591), our study should not discourage clinicians from prescribing PPIs to appropriate patients. While routine screening of serum magnesium concentrations in patients on PPIs is likely unwarranted, clinicians should be aware of this association, particularly in patients on long-term PPI therapy and those with hypokalemia or associated cardiac or neurologic symptoms. In patients with hypomagnesemia in the setting of PPI therapy, we suggest reassessing the need for ongoing therapy and considering other treatment options.

In summary, we found an association between outpatient PPI therapy and hospitalization with hypomagnesemia among older patients. Our findings highlight what may be an underappreciated adverse effect of PPI therapy. Future research may help further characterize the significance of this effect, and the importance of cumulative dose and duration of PPI therapy. In the interim, we suggest that physicians recognize the potential causative role of PPIs in patients with hypomagnesemia, and reconsider PPI therapy in such patients.

Supporting Information

Text S1 STROBE statement.
(DOC)

first draft of the manuscript: JZ. Wrote the paper: JZ EMM SH TG MMM JMP NL DNJ. ICMJE criteria for authorship read and met: JZ EMM SH TG MMM JMP NL DNJ. Agree with manuscript results and conclusions:

JZ EMM SH TG MMM JMP NL DNJ. Full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis: SH.

References

1. IMS Institute for Healthcare Informatics (2011) The Use of Medicine in the United States: Review of 2010. Available: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf. Accessed 10 April 2014.

2. Richardson P, Hawkey CJ, Stack WA (1998) Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56: 307–335.

3. Salas M, Ward A, Caro J (2002) Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2: 17.

4. Poynard T, Lemaire M, Agostini H (1995) Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 7: 661–665.

5. Leonard J, Marshall JK, Moayyedi P (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102: 2047–56; quiz 2057.

6. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, et al. (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107: 1011–1019.

7. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107: 1001–1010.

8. Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, et al. (2012) Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 21: 1155–1172.

9. Blank M-L, Parkin L, Paul C, Herbison P (2014) A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. doi: 10.1038/ki.2014.74

10. Eom C-S, Jeon CY, Lim J-W, Cho E-G, Park SM, et al. (2011) Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 183: 310–319.

11. Marcuard SP, Albernaz L, Khazanie PG (1994) Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 120: 211–215.

12. Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124: 519–526.

13. Famularo G, Gasbarrone L, Minisola G (2013) Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf: 1–8.

14. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, et al. (1995) Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 48: 927–940.

15. Schimatschek HF, Rempis R (2001) Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res 14: 283–290.

16. Schlingmann KP, Waldegger S, Konrad M, Chubanov V, Gudermann T (2007) TRPM6 and TRPM7–Gatekeepers of human magnesium metabolism. Biochim Biophys Acta 1772: 813–821.

17. Weisinger JR, Bellorin-Font E (1998) Magnesium and phosphorus. Lancet 352: 391–396.

18. Epstein M, McGrath S, Law F (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 355: 1834–1836.

19. Arulanantham N, Anderson M (2011) A 63-year-old man with hypomagnesaemia and seizures. Clin Med (Northfield, Il) 11: 591–593.

20. Broeren M, Geerdink E (2009) Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern 151: 755–756.

21. Fernandez-Fernandez F (2010) Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med 68: 329–330.

22. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW (2008) Omeprazole and refractory hypomagnesaemia. BMJ 337: a425.

23. Cundy T, Dissanayake a (2008) Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 69: 338–341.

24. Famularo G, Minisola G, Bravi MC, Colucci P, Gasbarrone L (2012) Tetany, hypomagnesemia, and proton-pump inhibitors. Am J Med 125: e7–e8.

25. Hoorn EJ, van der Hoek J, de Man R a, Kuipers EJ, Bolwerk C, et al. (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56: 112–116.

26. Mackay JD, Bladon PT (2010) Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 103: 387–395.

27. Hess MW, Hoenderop JGJ, Bindels RJM, Drenth JPH (2012) Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 36: 405–413.

28. Furlanetto TW, Faulhaber GAM (2011) Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 171: 1391–1392.

29. Matsuyama J, Tsuji K, Doyama H, Kim F, Takeda Y, et al. (2012) Hypomagnesemia Associated with a Proton Pump Inhibitor. Intern Med 51: 2231–2234.

30. Gandhi NY, Sharif WK, Chadha S, Shakher J (2012) A patient on long-term proton pump inhibitors develops sudden seizures and encephalopathy: an unusual presentation of hypomagnesaemia. Case Rep Gastrointest Med 2012: 632721.

31. Danziger J, William JH, Scott DJ, Lee J, Lehman L, et al. (2013) Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 83: 692–699.

32. Gau J, Yang Y (2012) Uses of proton pump inhibitors and hypomagnesemia. … drug Saf: 553–559.

33. Koulouridis I, Alfayez M, Tighiouart H, Madias NE, Kent DM, et al. (2013) Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 62: 730–737.

34. Luk CP, Parsons R, Lee YP, Hughes JD (2013) Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 47: 773–780.

35. Hux JE, Ivis F, Flintoft V, Bica A (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25: 512–516.

36. Schultz SE, Rothwell DM, Chen Z, Tu K (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33: 160–166.

37. Juurlink DN, Mhsc TG, Ko DT, Szmitko PE, Austin PC, et al. (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713–718.

38. Juurlink D, Gomes T, Lipscombe L, Austin PC, Hux J, et al. (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339: 1–6.

39. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, et al. (2006) Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354: 1352–1361.

40. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, et al. (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154: 854–864.

41. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E (2010) Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 56: 168–174.

42. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, et al. (2002) Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 31: 171–174.

43. Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, et al. (2004) Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci U S A 101: 2894–2899.

44. Lainez S, Schlingmann KP, van der Wijst J, Dworniczak B, van Zeeland F, et al. (2013) New TRPM6 missense mutations linked to hypomagnesemia with secondary hypocalcemia. Eur J Hum Genet: 1–8.

45. Elin RJ (2010) Assessment of magnesium status for diagnosis and therapy. Magnes Res 23: S194–S1988.